Information Provided By:
Fly News Breaks for April 5, 2018
DBVT, AIMT
Apr 5, 2018 | 06:07 EDT
Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $62 price target after speaking to a community-based allergist whose practice he feels is representative of the U.S. peanut allergy market. The analyst heard three key takeaways that reinforce his thesis for Aimmune's AR101 market potential: Both safety/tolerability are better than expected and completely feasible in most of his patients, several patient segments will likely prefer AR101 in his practice, and there is likely very high demand for any immunotherapy with community doctors likely to use both AR101 and DBV Technologies' (DBVT) Viaskin, if both are approved.
News For AIMT;DBVT From the Last 2 Days
There are no results for your query AIMT;DBVT